281 related articles for article (PubMed ID: 34220718)
21. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
[TBL] [Abstract][Full Text] [Related]
22. Performance of DAXX Immunohistochemistry as a Screen for DAXX Mutations in Pancreatic Neuroendocrine Tumors.
Hechtman JF; Klimstra DS; Nanjangud G; Frosina D; Shia J; Jungbluth AA
Pancreas; 2019 Mar; 48(3):396-399. PubMed ID: 30747827
[TBL] [Abstract][Full Text] [Related]
23. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
[TBL] [Abstract][Full Text] [Related]
24. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
[TBL] [Abstract][Full Text] [Related]
25. Altered telomeres in tumors with ATRX and DAXX mutations.
Heaphy CM; de Wilde RF; Jiao Y; Klein AP; Edil BH; Shi C; Bettegowda C; Rodriguez FJ; Eberhart CG; Hebbar S; Offerhaus GJ; McLendon R; Rasheed BA; He Y; Yan H; Bigner DD; Oba-Shinjo SM; Marie SK; Riggins GJ; Kinzler KW; Vogelstein B; Hruban RH; Maitra A; Papadopoulos N; Meeker AK
Science; 2011 Jul; 333(6041):425. PubMed ID: 21719641
[TBL] [Abstract][Full Text] [Related]
26. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.
Chan CS; Laddha SV; Lewis PW; Koletsky MS; Robzyk K; Da Silva E; Torres PJ; Untch BR; Li J; Bose P; Chan TA; Klimstra DS; Allis CD; Tang LH
Nat Commun; 2018 Oct; 9(1):4158. PubMed ID: 30315258
[TBL] [Abstract][Full Text] [Related]
27. Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort.
Ban X; Mo S; Lu Z; Jia C; Shao H; Yan J; Chang X; Mao X; Wu Y; Zhang Y; Fan X; Yu S; Chen J
Neuroendocrinology; 2022; 112(5):510-522. PubMed ID: 34348341
[TBL] [Abstract][Full Text] [Related]
28. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865
[TBL] [Abstract][Full Text] [Related]
29. Daxx Functions Are p53-Independent
Wasylishen AR; Estrella JS; Pant V; Chau GP; Lozano G
Mol Cancer Res; 2018 Oct; 16(10):1523-1529. PubMed ID: 29903771
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?
Marinoni I
Gut; 2022 May; 71(5):847-848. PubMed ID: 33975869
[No Abstract] [Full Text] [Related]
31. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.
Yadav R; Kakkar A; Sharma A; Malik PS; Sharma MC
Scand J Gastroenterol; 2016 Aug; 51(8):994-9. PubMed ID: 27162024
[TBL] [Abstract][Full Text] [Related]
32. Impact of DAXX and ATRX expression on telomere length and prognosis of breast cancer patients.
Hussien MT; Shaban S; Temerik DF; Helal SR; Mosad E; Elgammal S; Mostafa A; Hassan E; Ibrahim A
J Egypt Natl Canc Inst; 2020 Aug; 32(1):34. PubMed ID: 32856116
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.
Chen SF; Kasajima A; Yazdani S; Chan MS; Wang L; He YY; Gao HW; Sasano H
Hum Pathol; 2013 Oct; 44(10):2199-203. PubMed ID: 23954140
[TBL] [Abstract][Full Text] [Related]
34. Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo.
Wasylishen AR; Sun C; Moyer SM; Qi Y; Chau GP; Aryal NK; McAllister F; Kim MP; Barton MC; Estrella JS; Su X; Lozano G
Sci Adv; 2020 Aug; 6(32):eaba8415. PubMed ID: 32821827
[TBL] [Abstract][Full Text] [Related]
35. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract][Full Text] [Related]
36. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
37. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
[TBL] [Abstract][Full Text] [Related]
38. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.
de Wilde RF; Edil BH; Hruban RH; Maitra A
Nat Rev Gastroenterol Hepatol; 2012 Feb; 9(4):199-208. PubMed ID: 22310917
[TBL] [Abstract][Full Text] [Related]
39. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
[TBL] [Abstract][Full Text] [Related]
40. Expression and prognostic impact of alpha thalassemia/mental retardation X-linked and death domain-associated protein in human lung cancer.
Buentzel J; Yao S; Elakad O; Lois AM; Brünies J; König J; Hinterthaner M; Danner BC; Ströbel P; Emmert A; Bohnenberger H
Medicine (Baltimore); 2019 Aug; 98(31):e16712. PubMed ID: 31374064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]